Shares of Enhabit, Inc. (NYSE:EHAB – Get Free Report) have been assigned an average rating of “Reduce” from the seven research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $9.25.
Separately, Leerink Partners restated a “market perform” rating and issued a $8.00 price objective (down from $8.50) on shares of Enhabit in a report on Tuesday, November 19th.
Read Our Latest Stock Analysis on Enhabit
Institutional Investors Weigh In On Enhabit
Enhabit Stock Performance
Shares of NYSE:EHAB opened at $7.56 on Tuesday. The firm’s 50 day simple moving average is $7.50 and its 200-day simple moving average is $8.40. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.46 and a current ratio of 1.46. Enhabit has a one year low of $6.85 and a one year high of $11.74. The firm has a market cap of $380.12 million, a PE ratio of -3.26 and a beta of 1.84.
Enhabit (NYSE:EHAB – Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.01). The firm had revenue of $253.60 million for the quarter, compared to analysts’ expectations of $261.69 million. Enhabit had a positive return on equity of 1.67% and a negative net margin of 11.24%. During the same quarter in the previous year, the business earned $0.03 earnings per share. As a group, equities analysts predict that Enhabit will post 0.22 EPS for the current year.
Enhabit Company Profile
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
Featured Stories
- Five stocks we like better than Enhabit
- Overbought Stocks Explained: Should You Trade Them?
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
- NYSE Stocks Give Investors a Variety of Quality Options
- MarketBeat Week in Review – 11/18 – 11/22
- What is the NASDAQ Stock Exchange?
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.